Senzar Asset Management’s Theravance Biopharma TBPH Stock Holding History

Senzar Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-27,397	Closed	-$621K	–	14
2018 Q2	$621K	Sell	27,397 -160,459	-85%	-$3.81M	1.79%	14
2018 Q1	$4.55M	Buy	187,856 +16,056	+9%	+$441K	1.44%	28
2017 Q4	$4.79M	Sell	171,800 -10,300	-6%	-$305K	1.22%	26
2017 Q3	$6.24M	Buy	+182,100	New	+$5.95M	1.52%	21

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Senzar Asset Management's TBPH Position: Q3 2018 in Review

Senzar Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2018, closing a stake of 27,397 shares — an estimated $621K sold.

Senzar Asset Management first reported a position in TBPH in Q3 2017 and held it in 4 quarters. The position peaked at $6.24M in Q3 2017. 93 funds tracked by Wall St. Rank hold TBPH as of Q3 2018.

Senzar Asset Management reported no remaining Theravance Biopharma position as of Q3 2018 after selling out during the quarter.
Senzar Asset Management sold 27,397 Theravance Biopharma shares in Q3 2018, an estimated $621K.
Senzar Asset Management first reported a position in Theravance Biopharma in Q3 2017 and held it in 4 quarters.
Senzar Asset Management's Theravance Biopharma position peaked at $6.24M in Q3 2017.
93 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2018.

Based on Senzar Asset Management's 13F filing for Q3 2018.